1-156136110-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2PP5_Very_Strong
The NM_170707.4(LMNA):c.1146C>T(p.Gly382Gly) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. G382G) has been classified as Likely pathogenic.
Frequency
Genomes: 𝑓 0.0 ( 0 hom., cov: 32)
Failed GnomAD Quality Control
Consequence
LMNA
NM_170707.4 synonymous
NM_170707.4 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.481
Genes affected
LMNA (HGNC:6636): (lamin A/C) The protein encoded by this gene is part of the nuclear lamina, a two-dimensional matrix of proteins located next to the inner nuclear membrane. The lamin family of proteins make up the matrix and are highly conserved in evolution. During mitosis, the lamina matrix is reversibly disassembled as the lamin proteins are phosphorylated. Lamin proteins are thought to be involved in nuclear stability, chromatin structure and gene expression. Vertebrate lamins consist of two types, A and B. Alternative splicing results in multiple transcript variants. Mutations in this gene lead to several diseases: Emery-Dreifuss muscular dystrophy, familial partial lipodystrophy, limb girdle muscular dystrophy, dilated cardiomyopathy, Charcot-Marie-Tooth disease, and Hutchinson-Gilford progeria syndrome. [provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 1-156136110-C-T is Pathogenic according to our data. Variant chr1-156136110-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 48032.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-156136110-C-T is described in Lovd as [Pathogenic]. Variant chr1-156136110-C-T is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LMNA | NM_170707.4 | c.1146C>T | p.Gly382Gly | synonymous_variant | 6/12 | ENST00000368300.9 | NP_733821.1 | |
LMNA | NM_005572.4 | c.1146C>T | p.Gly382Gly | synonymous_variant | 6/10 | ENST00000677389.1 | NP_005563.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LMNA | ENST00000368300.9 | c.1146C>T | p.Gly382Gly | synonymous_variant | 6/12 | 1 | NM_170707.4 | ENSP00000357283.4 | ||
LMNA | ENST00000677389.1 | c.1146C>T | p.Gly382Gly | synonymous_variant | 6/10 | NM_005572.4 | ENSP00000503633.1 |
Frequencies
GnomAD3 genomes AF: 0.00 AC: 0AN: 152140Hom.: 0 Cov.: 32 FAILED QC
GnomAD3 genomes
AF:
AC:
0
AN:
152140
Hom.:
Cov.:
32
FAILED QC
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome Cov.: 34
GnomAD4 exome
Cov.:
34
GnomAD4 genome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 152140Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74318
GnomAD4 genome
Data not reliable, filtered out with message: AC0
AF:
AC:
0
AN:
152140
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74318
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:11Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:7Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | May 24, 2023 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | AiLife Diagnostics, AiLife Diagnostics | Jun 02, 2020 | - - |
Likely pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jan 03, 2017 | - - |
not provided, no classification provided | literature only | Epithelial Biology; Institute of Medical Biology, Singapore | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2024 | LMNA: PVS1:Strong, PM2, PS4:Moderate, PS3:Supporting - |
Likely pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Apr 01, 2024 | Observed in association with limb-girdle muscular dystrophy, arrhythmia, and dilated cardiomyopathy (DCM) in individuals referred for genetic testing at GeneDx and in the published literature (PMID: 24503780, 17377071); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis, which includes splice predictors and evolutionary conservation, predict the creation of a strong cryptic splice donor site upstream of the natural donor site in intron 6; Published mRNA functional studies demonstrated creation of a cryptic splice donor site in the 3' end of exon 6, resulting in a deletion of the last 13 nucleotides of exon 6 and a premature stop codon 93 amino acids downstream (PMID: 17377071); This variant is associated with the following publications: (PMID: 27506821, 24915601, 28679633, 28798025, 29582363, 31447099, Ferradini2021[publication], 24503780, 17377071) - |
Primary dilated cardiomyopathy;C0027868:Neuromuscular disease Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | May 25, 2018 | The p.Gly382Gly variant in LMNA has been previously reported in 1 individual wit h LVNC, 2 individuals with DCM and conduction system disease, and 1 individual w ith childhood-onset limb-girdle muscular dystrophy and adult-onset DCM with SVT (Benedetti 2007, Di Resta 2014, Ito 2017, Miszalski-Jamka 2017, LMM Data). It al so segregated with DCM in 2 affected relative. This variant has also been report ed by other clinical laboratories in ClinVar (Variation ID: 48032). This variant was absent from large population studies. This variant does not alter the amino acid residue, but RNA studies showed that it creates a new splice site in the 3 ' end of exon 6 resulting in the deletion of the remaining 13 bases in this exon (Benedetti 2007, Di Resta 2014). This deletion causes a frameshift, altering th e protein's amino acid sequence beginning at codon 383 and leading to a prematur e stop codon 93 amino acids downstream, which is predicted to lead to a truncate d or absent protein. In summary, although additional studies are required to ful ly establish its clinical significance, the p.Gly382Gly variant is likely pathog enic. ACMG/AMP criteria applied: PS3, PM2, PS4_Supporting. - |
Charcot-Marie-Tooth disease type 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 27, 2024 | This sequence change affects codon 382 of the LMNA mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the LMNA protein. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individuals with cardiomyopathy and conduction disease and/or limb-girdle muscular dystrophy (PMID: 17377071, 27506821; Invitae). ClinVar contains an entry for this variant (Variation ID: 48032). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Dilated cardiomyopathy 1A Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | Sangiuolo Lab - Medical Genetics Laboratory, Tor Vergata University | Apr 27, 2021 | - - |
Cardiovascular phenotype Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 08, 2021 | The c.1146C>T variant (also known as p.G382G), located in coding exon 6, results from a C to T substitution at nucleotide position 1146 of the LMNA gene. This nucleotide substitution does not change the amino acid at codon 382. This alteration has been reported in individuals with limb-girdle muscular dystrophy, dilated cardiomyopathy (DCM), and cardiac conduction disease (Benedetti S et al. Neurology, 2007 Sep;69:1285-92; Di Resta C et al. Clin. Chim. Acta, 2014 Sep;436:276-82). This alteration was also reported in DCM and left ventricular non-compaction cohorts, but clinical details were limited and some patients had additional variants in other cardiac-related genes (Pugh TJ et al. Genet. Med., 2014 Aug;16:601-8; Miszalski-Jamka K et al. Circ Cardiovasc Genet, 2017 Aug;10:[Epub ahead of print]). This nucleotide position is not well conserved in available vertebrate species, and threonine is the reference nucleotide in other vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and will result in the creation or strengthening of a novel splice donor site. Published RNA studies have demonstrated this alteration leads to the creation of a new splice donor site, which leads to deletion of the last 13 nucleotides of exon 6, causing a frameshift that introduces a premature stop codon (Benedetti S et al. Neurology, 2007 Sep;69:1285-92; Di Resta C et al. Clin. Chim. Acta, 2014 Sep;436:276-82). Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_DG_spliceai
Position offset: -2
DS_DL_spliceai
Position offset: 11
Find out detailed SpliceAI scores and Pangolin per-transcript scores at